Published June 2016 | Version v1
Journal article

PET imaging of prostate cancer with 18F-Al-NODA-MATBBN

  • 1. Jiangsu Institute of Nuclear Medicine, Jiangsu (China). Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine
  • 2. Nanjing Medical University, Jiangsu (China). Department of Nuclear Medicine, Affiliated Wuxi People's Hospital

Description

We explored the application of new bifunctional chelating agent p-SCN-NODA by conjugating to GRPR targeting peptide, MATBBN. p-SCN-NODA can increase the labeling yield to 68.3 ± 1.8 %. 18F-Al-NODA-MATBBN can be produced within 25 min with a radiochemical purity of more than 98 %. At 30 min post-injection, the tumor uptake for 18F-Al-NODA-MATBBN was 3.23 ± 0.23 % ID/g. Biodistribution studies revealed that 18F-Al-NODA-MATBBN was excreted mainly through the kidneys. GRPR-binding specificity was also demonstrated by reduced tumor uptake of 18F-Al-NODA-MATBBN after co-injection with excess unlabeled MATBBN peptide at 1 h post-injection. It suggests that 18F-Al-NODA-MATBBN may be a potential PET tracer candidate for monitoring prostate cancer. (author)

Additional details

Publishing Information

Journal Title
Journal of Radioanalytical and Nuclear Chemistry
Journal Volume
308
Journal Issue
3
Journal Page Range
p. 905-911
ISSN
0236-5731
CODEN
JRNCDM

Optional Information

Notes
19 refs.